Compare Access Scientific vs Myconostica

Myconostica is 18 yrs old and is based in United Kingdom.

Myconostica Ltd develops and supplies molecular diagnostic products to aid rapid and accurate diagnosis of life-threatening invasive fungal infections. nnTraditional methods for the detection of fungal pathogens, such as culture and microscopy, are well-documented as being relatively insensitive and slow. Myconostica will use advances in molecular techniques, such as Real-Time PCR, to develop a range of assays for the rapid, accurate and sensitive detection of fungi such as Aspergillus spp., Pneumocystis jirovecii and Candida spp. Evidence shows that an early diagnosis of invasive fungal infection aims to improve the chance of survival. Tests provided by Myconostica will aim to allow healthcare professionals to rapidly identify those patients infected by invasive fungal pathogens thus enabling clinicians to prescribe appropriate drug therapy. Early identification of disease aims to reduce the patient's exposure to inappropriate drug treatments, aims to improve patient outcomes and aims to reduce the hospitalisation and treatment costs associated with invasive fungal disease. The company are a spin-out company of the University of Manchester, and a Partner Company of Amphion Innovations plc. (Amphion, AIM: AMP, develops and operates companies in the life sciences and technology sectors). n